Due to their capacity to transport proteins, lipids as well as nucleic acid,s extracellular vesicles (EVs) play an important role in cellular communication and have gained ever increasing importance in the fields of regenerative medicine, anti-tumor therapy or immunotherapy. Specifically, EVs secreted from human stem cells have been reported to be equally effective as the transplanted cells in various disease models. Therefore, Evercyte has put a focus on the development of human cells that produce EVs with therapeutic activity.
Additionally, human highly specialized cells qualify for production of recombinant proteins or vaccines. Today, more than 60% of recombinant proteins used for therapeutic applications are produced in mammalian cells, which is due to appropriate protein folding, assembly and posttranslational modification, factors that are major determinants for the biological activity and product quality. However, most commonly used mammalian cell factories have e.g. abnormal glycosylation patterns and thus may produce protein isoforms that differ from those synthesized in normal cells. Furthermore, differences in the glycosylation patterns produced by cells from different tissues accentuate the need for selection and establishment of novel host cell lines.
Evercyte´s telomerized cell lines show stable growth characteristics and phenotypes and have a high potential for production of complex biopharmaceuticals. Evercyte provides cell factories that allow production of Evs also for clinical application. Moreover, we offer customer-tailored cell line development services.